Interestingly, Foretinib is an ATP-competitive inhibitor of tyrosine kinases, and both acute leukemia cell lines with the lowest IC50 values to this drug carried FLT3 activating mutations (MONO-MAC-6, p.V592A; MOLM-13, ITD). This evidence concerns the gene FLT3 and acute leukemia.